朱海波;江名芳;海俊杰;刘雅虹;

• 1:内蒙古医科大学内蒙古医科大学附属医院

摘要(Abstract)：

帕金森病是一种起病隐匿的神经退行性疾病，为及时诊断及监测治疗提出了挑战，18-氟代脱氧葡萄糖正电子发射断层扫描（⁽¹⁸⁾F-FDG PET-CT）是一种分子影像学标志物，可以根据脑内葡萄糖代谢变化客观表现帕金森病的病情进展。目前研究表明，其代谢模式可以用于帕金森病监测治疗、疾病预测方向，本文对(18)F-FDG PET-CT）是一种分子影像学标志物，可以根据脑内葡萄糖代谢变化客观表现帕金森病的病情进展。目前研究表明，其代谢模式可以用于帕金森病监测治疗、疾病预测方向，本文对⁽¹⁸⁾F-FDG PET-CT的成像原理、PD相关代谢模式、PD相关的认知模式，特发性快速眼动睡眠障碍相关模式做一综述。

关键词(KeyWords)： ~(18)F-FDG PET-CT;帕金森病;葡萄糖代谢模式;PD相关代谢模式;PD相关认知模式;特发性快速眼动睡眠障碍

Abstract:

Keywords:

基金项目(Foundation): 内蒙古自治区科技计划项目（编号：2021GG0233）

作者(Authors): 朱海波;江名芳;海俊杰;刘雅虹;

参考文献(References)：

• [1]SONG Z,LIU S,LI X,et al.Prevalence of Parkinson’s Disease in Adults Aged 65 Years and Older in China:A Multicenter Population-Based Survey[J].Neuroepidemiology,2022,56(1):50-58.DOI:10.1159/000520726.
• [2]张硕，高健，姜立刚.帕金森病患病率及相关因素的流行病学研究现状[J].吉林医药学院学报，2021,42(6):437-439.
• [3]葛璟洁，李玲，刘丰韬，等.帕金森病/帕金森综合征（18)F-FDGPET脑显像技术操作及报告解读要素[J].中国临床神经科学，2021,29(1):82-87.
• [4]FENG H,WANG X,CHEN J,et al.Nuclear Imaging of Glucose Metabolism:Beyond 18F-FDG[J].Contrast Media Mol Imaging,2019,2019:7954854.DOI:10.1155/2019/7954854.
• [5]BURNS R,MULéS,BLANC-DURAND P,et al.Optimization of whole-body2-[18F]FDG-PET/MRI imaging protocol for the initial staging of patients with myeloma[J].Eur Radiol,2022,32(5):3085-3096.DOI:10.1007/s00330-021-08388-6.
• [6]MELES S K,TEUNE L K,DE JONG B M,et al.Metabolic imaging in Parkinson Disease[J].J Nucl Med,2017,58(1):23-28.
• [7]李少林主编.核医学[M].5版.北京：人民卫生出版社，2002:91.
• [8]KO J H,LEE C S,EIDELBERG D.Metabolic network expression in parkinsonism:Clinical and dopaminergic correlations[J].JCereb Blood Flow Metab,2017,37(2):683-693.
• [9]尚琨，乔洪文，卢洁，等.（18)F-FDG及（18)F-FP-DTBZ双示踪PET/CT显像诊断帕金森病[J].中国医学影像技术，2018,34(11):1615-1620.DOI:10.13929/j.1003-3289.201803156.
• [10]MEYER P T,FRINGS L,RüCKER G,et al.18F-FDG PET in Parkinsonism:Differential Diagnosis and Evaluation of Cognitive Impairment[J].J Nucl Med,2017,58(12):1888-1898.DOI:10.2967/jnumed.116.186403.
• [11]SHIN J H,LEE J Y,KIM Y K,et al.Parkinson Disease-Related Brain Metabolic Patterns and Neurodegeneration in Isolated REM Sleep Behavior Disorder[J].Neurology,2021,97(4):e378-e388.DOI:10.1212/WNL.0000000000012228.
• [12]EIDELBERG D,MOELLER J R,DHAWAN V,et al.The metabolic topography of parkinsonism[J].J Cereb Blood Flow Metab,1994,14(5):783-801.DOI:10.1038/jcbfm.1994.99.
• [13]WANG H,TIAN Y,LIU Y,et al.Population-specific brain[18F]-FDG PET templates of Chinese subjects for statistical parametric mapping[J].Sci Data,2021,8(1):305.DOI:10.1038/s41597-021-01089-1.
• [14]DELONG M R,WICHMANN T.Basal Ganglia Circuits as Targets for Neuromodulation in Parkinson Disease[J].JAMA Neurol,2015,72(11):1354-1360.DOI:10.1001/jamaneurol.2015.2397.
• [15]OSWAL A,CAO C,YEH C H,et al.Neural signatures of hyperdirect pathway activity in Parkinson’s disease[J].Nat Commun,2021,12 (1):5185.DOI:10.1038/s41467-021-25366-0.
• [16]MATTHEWS D C,LERMAN H,LUKIC A,et al.FDG PETParkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease[J].Neuroimage Clin,2018,20:572-579.DOI:10.1016/j.nicl.2018.08.006.
• [17]SHEN B,WEI S,GE J,et al.Reproducible metabolic topographies associated with multiple system atrophy:Network and regional analyses in Chinese and American patient cohorts[J].Neuroimage Clin,2020,28:102416.DOI:10.1016/j.nicl.2020.102416.
• [18]MELES S K,RENKEN R J,PAGANI M,et al.Abnormal pattern of brain glucose metabolism in Parkinson’s disease:replication in three European cohorts[J].Eur J Nucl Med Mol Imaging,2020,47(2):437-450.DOI:10.1007/s00259-019-04570-7.
• [19]WU P,WANG J,PENG S,et al.Metabolic brain network in the Chinese patients with Parkinson’s disease based on 18F-FDGPET imaging[J].Parkinsonism Relat Disord,2013,19(6):622-627.DOI:10.1016/j.parkreldis.2013.02.013.
• [20]JANKOVIC J,TAN E K.Parkinson’s disease:etiopathogenesis and treatment[J].J Neurol Neurosurg Psychiatry,2020,91(8):795-808.DOI:10.1136/jnnp-2019-322338.
• [21]TRENKWALDER C,KUOPPAM?KI M,VAHTERISTO M,et al.Increased dose of carbidopa with levodopa and entacapone improves“off”time in a randomized trial[J].Neurology,2019,92(13):e1487-e1496.DOI:10.1212/WNL.0000000000007173.
• [22]LATT M D,LEWIS S,ZEKRY O,et al.Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease[J].Drugs Aging,2019,36(3):189-202.DOI:10.1007/s40266-018-0629-0.
• [23]DAFSARI H S,MARTINEZ-MARTIN P,RIZOS A,et al EUROPAR and the International Parkinson and Movement Disorders Society Non-Motor Parkinson‘s Disease Study Group.Euro Inf 2:Subthalamic stimulation,apomorphine,and levodopa infusion in Parkinson’s disease[J].Mov Disord,2019,34(3):353-365.DOI:10.1002/mds.27626.
• [24]MARTíNEZ-FERNáNDEZ R,RODRíGUEZ-ROJAS R,DELáLAMO M,et al.Focused ultrasound subthalamotomy in patients with asymmetric Parkinson’s disease:a pilot study[J].Lancet Neurol,2018,17(1):54-63.DOI:10.1016/S1474-4422(17)30403-9.
• [25]FEIGIN A,FUKUDA M,DHAWAN V,et al.Metabolic correlates of levodopa response in Parkinson’s disease[J].Neurology,2001,57(11):2083-2088.DOI:10.1212/wnl.57.11.2083.
• [26]林清江，魏吟秋.普拉克索加多巴丝肼片对帕金森病的治疗效果[J].中外医学研究，2021,19(27):151-153.
• [27]GE J,WANG M,LIN W,et al.Metabolic network as an objective biomarker in monitoring deep brain stimulation for Parkinson’s disease:a longitudinal study[J].EJNMMI Res,2020,10(1):131.DOI:10.1186/s13550-020-00722-1.
• [28]EVERS L J W,KRIJTHE J H,MEINDERS M J,et al.Measuring Parkinson’s disease over time:The real-world within-subject reliability of the MDS-UPDRS[J].Mov Disord,2019,34(10):1480-1487.DOI:10.1002/mds.27790.
• [29]ASANUMA K,TANG C,MA Y,et al.Network modulation in the treatment of Parkinson’s disease[J].Brain,2006,129(Pt10):2667-2678.DOI:10.1093/brain/awl162.
• [30]CAO C,ZHANG H,LI D,et al.Modified Fluorodeoxyglucose Metabolism in Motor Circuitry by Subthalamic Deep Brain Stimulation[J].Stereotact Funct Neurosurg,2017,95 (2):93-101.DOI:10.1159/000455930.
• [31]VIZCARRA J A,SITU-KCOMT M,ARTUSI C A,et al.Subthalamic deep brain stimulation and levodopa in Parkinson’s disease:a meta-analysis of combined effects[J].J Neurol,2019,266(2):289-297.DOI:10.1007/s00415-018-8936-2.
• [32]LEE E J,OH J S,MOON H,et al.Parkinson Disease-Related Pattern of Glucose Metabolism Associated With the Potential for Motor Improvement After Deep Brain Stimulation[J].Neurosurgery,2020,86(4):492-499.DOI:10.1093/neuros/nyz206.
• [33]LIU F T,LANG L Q,YANG Y J,et al.Predictors to quality of life improvements after subthalamic stimulation in Parkinson’s disease[J].Acta Neurol Scand,2019,139(4):346-352.DOI:10.1111/ane.13056.
• [34]RODRIGUEZ-ROJAS R,PINEDA-PARDO J A,MARTINEZ-FERNANDEZ R,et al.Functional impact of subthalamotomy by magnetic resonance-guided focused ultrasound in Parkinson’s disease:a hybrid PET/MR study of resting-state brain metabolism[J].Eur J Nucl Med Mol Imaging,2020,47(2):425-436.DOI:10.1007/s00259-019-04497-z.
• [35]LAWSON R A,YARNALL A J,DUNCAN G W,et al.ICICLE-PD study group.Stability of mild cognitive impairment in newly diagnosed Parkinson’s disease[J].J Neurol Neurosurg Psychiatry,2017,88(8):648-652.DOI:10.1136/jnnp-2016-315099.
• [36]BOCK M A,TANNER C M.The epidemiology of cognitive function in Parkinson’s disease[J].Prog Brain Res,2022,269(1):3-37.DOI:10.1016/bs.pbr.2022.01.004.
• [37]WALLACE E R,SEGERSTROM S C,VAN HORNE C G,et al.Meta-Analysis of Cognition in Parkinson’s Disease Mild Cognitive Impairment and Dementia Progression[J].Neuropsychol Rev,2022,32(1):149-160.DOI:10.1007/s11065-021-09502-7.
• [38]HARVEY P D.Domains of cognition and their assessment[J].Dialogues Clin Neurosci,2019,21(3):227-237.DOI:10.31887/DCNS.2019.21.3/pharvey.
• [39]HUANG C,MATTIS P,TANG C,et al.Metabolic brain networks associated with cognitive function in Parkinson’s disease[J].Neuroimage,2007,34(2):714-23.DOI:10.1016/j.neuroimage.2006.09.003.
• [40]MELES S K,TANG C C,TEUNE L K,et al.Abnormal metabolic pattern associated with cognitive impairment in Parkinson’s disease:a validation study[J].J Cereb Blood Flow Metab,2015,35(9):1478-1484.DOI:10.1038/jcbfm.2015.112.
• [41]SCHINDLBECK K A,VO A,MATTIS P J,et al.Cognition-Related Functional Topographies in Parkinson’s Disease:Localized Loss of the Ventral Default Mode Network[J].Cereb Cortex,2021,31(11):5139-5150.DOI:10.1093/cercor/bhab148.
• [42]NIETHAMMER M,TANG C C,MA Y,et al.Parkinson’s disease cognitive network correlates with caudate dopamine[J].Neuroimage,2013,78:204-209.DOI:10.1016/j.neuroimage.2013.03.070.
• [43]MATTIS P J,NIETHAMMER M,SAKO W,et al.Distinct brain networks underlie cognitive dysfunction in Parkinson and Alzheimer diseases[J].Neurology,2016,87(18):1925-1933.DOI:10.1212/WNL.0000000000003285.
• [44]SHEN C,CHEN L,GE J J,et al.Cerebral Metabolism Related to Cognitive Impairments in Multiple System Atrophy[J].Front Neurol,2021,12:652059.DOI:10.3389/fneur.2021.652059.
• [45]吴昊，纪勇.快速眼球运动睡眠期行为障碍与α-突触核蛋白病的关系研究进展[J].中国实用神经疾病杂志，2021,24(24):2203-2208.DOI:10.12083/SYSJ.2021.24.012.
• [46]KOGAN R V,JANZEN A,MELES S K,et al.REMPET Working Group.Four-Year Follow-up of[18 F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson’s DiseaseRelated Pattern Expression in 20 Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression[J].Mov Disord,2021,36 (1):230-235.DOI:10.1002/mds.28260.
• [47]MELES S K,RENKEN R J,JANZEN A,et al.REMPET Study Group.The Metabolic Pattern of Idiopathic REM Sleep Behavior Disorder Reflects Early-Stage Parkinson Disease[J].J Nucl Med,2018,59(9):1437-1444.DOI:10.2967/jnumed.117.202242.
• [48]ARNALDI D,MELES S K,GIULIANI A,et al.REMPET Study Group.Brain Glucose Metabolism Heterogeneity in Idiopathic REM Sleep Behavior Disorder and in Parkinson’s Disease[J].JParkinsons Dis,2019,9(1):229-239.DOI:10.3233/JPD-181468.
• [49]HAN X,WU P,ALBERTS I,et al.Characterizing the heterogeneous metabolic progression in idiopathic REM sleep behavior disorder[J].Neuroimage Clin,2020,27:102294.DOI:10.1016/j.nicl.2020.102294.
• [50]MATTIOLI P,PARDINI M,FAMàF,et al.Cuneus/precuneus as a central hub for brain functional connectivity of mild cognitive impairment in idiopathic REM sleep behavior patients[J].Eur JNucl Med Mol Imaging,2021,48(9):2834-2845.DOI:10.1007/s00259-021-05205-6.